Steadybase.

Definium Therapeutics, Inc.

Website Investor relations LinkedIn Latest 10-K
  • DFTX · Nasdaq
  • Medicinal Chemicals & Botanical Products
  • New York, NY
  • 105 employees
  • CIK 0001813814

Updated from SEC filings through

Top things to know

Executives

What leadership is saying

“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions”

Rob Barrow, Chief Executive Officer
Earnings press release (8-K Ex. 99.1), filed November 9, 2026

Definium Therapeutics, Inc. is a U.S. public company in medicinal chemicals & botanical products (SIC 2833), headquartered in New York, NY. It trades as DFTX on Nasdaq. It reported about 105 employees. Robert Barrow is Chief Executive Officer.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue Not on file Not on file Not on file Not on file Not on file
Operating income -$166M
10-K, 2026-02-26
-$104M
10-K, 2026-02-26
-$93.9M
10-K, 2025-03-06
-$66.3M
10-K, 2024-02-28
-$93.9M
10-K, 2023-03-09
SG&A $48.6M
10-K, 2026-02-26
$38.6M
10-K, 2026-02-26
$41.7M
10-K, 2025-03-06
$30.2M
10-K, 2024-02-28
$59.1M
10-K, 2023-03-09
Net income -$184M
10-K, 2026-02-26
-$109M
10-K, 2026-02-26
-$95.7M
10-K, 2025-03-06
-$56.8M
10-K, 2024-02-28
-$93.0M
10-K, 2023-03-09

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Robert Barrow
Chief Executive Officer at Definium Therapeutics
Chief Executive Officer Form 4, September 29, 2026
Brandi Roberts
Chief Financial Officer & Board Member
Chief Financial Officer Form 4, September 29, 2026
Daniel Karlin Chief Medical Officer Form 4, September 29, 2026
Mark Sullivan Chief Legal Officer Form 4, September 29, 2026
Matthew T. Wiley Chief Commercial Officer Form 4, September 29, 2026
Andreas Krebs Director 10-K, February 26, 2026
Carol Vallone Director 10-K, February 26, 2026
David Gryska Director 10-K, February 26, 2026
Roger Adsett Director 10-K, February 26, 2026
Roger Crystal Director 10-K, February 26, 2026
Suzanne Bruhn Director 10-K, February 26, 2026

What Definium Therapeutics, Inc. does

We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 136.9 million (as of November 2, 2026) 10-Q, November 9, 2026
Public float $488M (as of June 30, 2025) 10-K, February 26, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 9, 2026
Latest proxy statement Meeting June 11, 2026 (filed April 27, 2026) DEF 14A, April 27, 2026
Auditor Kpmg LLP (San Diego, California) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
September 25, 2026 Daniel Karlin
Chief Medical Officer
Sale 10,853 $397K Form 4, September 29, 2026
September 25, 2026 Robert Barrow
Chief Executive Officer
Sale 31,550 $1.2M Form 4, September 29, 2026
September 25, 2026 Matthew T. Wiley
Chief Commercial Officer
Sale 3,097 $113K Form 4, September 29, 2026
September 25, 2026 Mark Sullivan
Chief Legal Officer
Sale 14,051 $514K Form 4, September 29, 2026
September 25, 2026 Brandi Roberts
Chief Financial Officer
Sale 3,377 $123K Form 4, September 29, 2026
September 3, 2026 Robert Barrow
Chief Executive Officer
Sale 19,023 $722K Form 4, September 4, 2026
June 25, 2026 Mark Sullivan
Chief Legal Officer
Sale 13,008 $586K Form 4, June 26, 2026
June 25, 2026 Daniel Karlin
Chief Medical Officer
Sale 10,035 $452K Form 4, June 26, 2026

Recent 8-K events

Frequently asked questions about Definium Therapeutics, Inc.

What does Definium Therapeutics, Inc. do?
In its own words, from Item 1 of its 10-K: "We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders."
How many employees does Definium Therapeutics, Inc. have?
About 105 as of December 31, 2025, as stated in its annual report.
Who is the CEO of Definium Therapeutics, Inc.?
Robert Barrow, Chief Executive Officer, as named in a 4 filed September 29, 2026.
Who is the CFO of Definium Therapeutics, Inc.?
Brandi Roberts, Chief Financial Officer, as named in a 4 filed September 29, 2026.
Where is Definium Therapeutics, Inc. headquartered?
New York, NY.
What is Definium Therapeutics, Inc.'s stock ticker?
DFTX on Nasdaq.
What industry is Definium Therapeutics, Inc. in?
Medicinal Chemicals & Botanical Products, SIC code 2833.
What is Definium Therapeutics, Inc.'s website?
definiumtx.com. Investor relations: https://ir.definiumtx.com.
When does Definium Therapeutics, Inc. report earnings next?
January 18, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Definium Therapeutics, Inc. a public company?
Yes. Definium Therapeutics, Inc. files with the SEC under CIK 0001813814 and trades as DFTX.
Who audits Definium Therapeutics, Inc.?
Kpmg LLP, San Diego, California, as named in its latest annual report (10-K).
How many shares of Definium Therapeutics, Inc. are outstanding?
136.9 million shares as of November 2, 2026, from its 10-Q filed November 9, 2026.
What is Definium Therapeutics, Inc.'s public float?
$488M as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
How many business segments does Definium Therapeutics, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
When is Definium Therapeutics, Inc.'s annual shareholder meeting?
June 11, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
Have Definium Therapeutics, Inc. insiders traded stock recently?
Since September 25, 2025, officers and directors reported 20 open-market sales worth about $7.4M and 0 purchases on Forms 4 and 5. The most recent: Daniel Karlin (Chief Medical Officer) sold 10,853 shares on September 25, 2026.